All available clinical trials

This study reviews a new treatment to prevent memory decline and slow the earliest symptoms of Alzheimer’s disease.

Eligibility: Adults ages 55 to 80 with a reliable study partner to provide information; adults ages 55-64 must have a listed risk factor

A new approach to dementia treatment- targeting the proteins connected to memory loss.
Patients will receive 3TC, an FDA-approved drug commonly prescribed for HIV and Hepatitis B.
Research shows that 3TC slows the disease mechanisms present in the early phases of Alzheimer’s disease.

Eligibility: Adults, 50 to 80 years, diagnosed with Alzheimer’s disease

The purpose of this study is to evaluate if if the drug, Rapamycin, will reach the brain and effectively treat symptoms of Alzheimer’s disease and mild cognitive impairment using cerebrospinal fluid.

Eligibility: Adults, ages 55 to 85, diagnosed with mild cognitive impairment or early stages of Alzheimer’s disease

The purpose of this clinical trial is to collect data to study how gait patterns in older adults correlate with brain function.

Eligibility: Adults, over 65 years of age, with worsening memory, but no diagnosis of dementia, or have difficulty walking or climbing stairs.

The purpose of this clinical trial is to study heart function in relation to brain health.

Eligibility: Adults, ages 60 years or older, doctor referral with normal heart function or diastolic dysfunction and no significant memory concerns

The purpose of this study is to determine whether nicotine (in patch form) improves memory and functioning in adults diagnosed with mild cognitive impairment (MCI).

Eligibility: Healthy, non-smoking adults, age 55+ who notice changes in their memory or whose family member notice changes.

The REACH clinical trial is 1 of 16 trials worldwide offering promising therapies for Alzheimer’s disease and dementia funded by the Alzheimer’s Association’s Part the Cloud global research grant program and Bill Gates.
The trial will evaluate the use of Rapamycin to slow progression of amnestic mild cognitive impairment and early-stage Alzheimer’s. It will also collect vital information on Alzheimer’s markers and relevant outcomes for future clinical trials.

Eligibility: Adults, ages 55 to 89, diagnosed with mild cognitive impairment or Alzheimer’s disease

To provide easier, convenient testing in the future, this study will evaluate if at-home devices, like the FitBit, can detect these sleep disturbances in Parkinson’s with similar accuracy as a clinic-based sleep study.

Eligibility: Diagnosis of Parkinson’s disease and have a study partner that is knowledgeable about participant’s sleep habits

The purpose of this study is to evaluate if a combination of two medications may be an effective intervention for treating AD symptoms in future studies.

Eligibility: Adults, aged 65 years or older, with a diagnosis of Alzheimer’s disease